FDA Approves ALBUTEROL — Cipla USA Inc.

Cipla USA Inc. received FDA approval for the generic albuterol sulfate inhalation product, ANDA219409, marking a critical milestone as the branded competitor prepares for patent expiration. This clearance positions Cipla to immediately compete for market share in the massive respiratory franchise, likely triggering price reductions that could drive volume growth while pressuring the legacy brand’s dominance.